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Rab25-Mediated EGFR Recycling
Causes Tumor Acquired Radioresistance
Lu Zhang,1,2,3 Bowen Xie,1,2,3 Yanfang Qiu,1 Di Jing,1,3 Jing Zhang,1 Yumei Duan,4 Zhi Li,1,2 Ming Fan,3
Jiang He,1,2 Yuanzheng Qiu,5 Rong Tan,1,2 Jian Jian Li,3,6,* and Lun-Quan Sun1,2,7,8,*
SUMMARY
Tumor acquired radioresistance remains as themajor limit in cancer radiotherapy (RT). Rab25, a recep-
tor recycling protein, has been reported to be enhanced in tumors with aggressive phenotype and
chemotherapy resistance. In this study, elevated Rab25 expression was identified in an array of radio-
resistant human cancer cell lines, in vivo radioresistant xenograft tumors. Clinical investigation
confirmed that Rab25 expression was also associated with a worse prognosis in patients with lung
adenocarcinoma (LUAD) and nasopharyngeal carcinoma (NPC). Enhanced activities of EGFR were
observed in both NPC and LUAD radioresistant cells. Rab25 interacts with EGFR to enhance EGFR
recycling to cell surface and to decrease degradation in cytoplasm. Inhibition of Rab25 showed syner-
gized radiosensitivity with reduced aggressive phenotype. This study provides the clinical and exper-
imental evidence that Rab25 is a potential therapeutic target to alleviate the hyperactive EGFR
signaling and to prevent RT-acquired tumor resistance in patients with LUAD and NPC.
INTRODUCTION
More than 50% of solid tumors including lung adenocarcinoma (LUAD) and nasopharyngeal carcinoma
(NPC) are treated by radiotherapy (RT). However, to enhance the RT efficacy it remains urgent to invent
effective targets to eliminate the acquired resistance in treated tumor cells (Huang et al., 2013; Aravindan
et al., 2014; Begg et al., 2011). Among the major signaling pathways dominated in cancer cells, the activa-
tion of receptor tyrosine kinases (RTKs) has been identified to be the most frequent oncogenic event that
drives proliferation and malignant phenotype in tumor cells (Casaletto and Mcclatchey, 2012) and the acti-
vated EGFR is tightly associated with tumor response and prognosis after RT (Jakobsen et al., 2016; Higgins
et al., 2016). Targeting RTK suppresses tumor growth and synergizes the efficacy of RT (Camidge et al.,
2014). Although recycling of EGFR via endosomal pathway is able to enhance oncogenic potency and
tumor aggressive phenotype (Shapira et al., 2013; Ye et al., 2016), the mechanism of EGFR recycling under-
lying tumor adaptive radioresistance remains unsolved.
Both the endocytosis and recycling of EGFR could be enhanced when it is combined with its ligand EGF or
under stress condition (Ceresa, 2012; Tan et al., 2016). However, it is unclear how the two processes are coor-
dinated in EGFR-targeted therapy using small molecule tyrosine kinase inhibitors (TKIs) or EGFR-specific an-
tibodies (Chung et al., 2011; Ricordel et al., 2018). To treat tumors with the acquired resistance to TKIs, RT
among the others is a choice especially for treatment of local lesions. It has been identified that after endocy-
tosis, the ligand-bound EGFR is arrested in the endosomes via p38/MAPK, which has been linked with the cell
death induced by UV, TNFa, or cisplatin (Zwang and Yarden, 2006; Tomas et al., 2015). However, the mecha-
nism regulating the traffic and recycling of EGFR in RT-induced tumor adaptive resistance remains elusive.
Rab25, a member of the Rab11 family, predominantly expresses in epithelial cells and plays a key role in
recycling of endosome compartment (Hehnly and Doxsey, 2014). Enhanced GTPase activity is detected
in Rab25 compared with other recycling-endosome-related Rab proteins (Casanova et al., 1999). Accumu-
lating evidence suggests that Rab25 is actively involved in carcinogenesis and aggressive phenotype of tu-
mors (Cheng et al., 2012; Dozynkiewicz et al., 2012) and inhibition of Rab25 reduces the aggressive growth
in cancer cells (Mitra et al., 2017). Integrin a5b1 is reported to transport by Rab25-positive endosome
(Caswell et al., 2007). Rab25 collaborated with CLIC3 to recycle a5b1 in cells of pancreatic ductal adenocar-
cinoma to promote tumor aggression (Dozynkiewicz et al., 2012). Although both Rab25 and EGFR are sug-
gested to be involved in tumor response to therapies with gefitinib and migration (Jeong et al., 2018; Jo
et al., 2014), the interplay between these two factors in signaling tumor acquired radioresistance is to be
investigated.
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1
Using radioresistant tumor models from two human cancers mostly treated by RT, this study revealed a
previously unknown mechanism by which Rab25 enhances the aberrant transportation of EGFR in radia-
tion-adapted cancer cells. Rab25 is overexpressed in the radioresistant cancer cells and in radioresistant
xenograft tumors treated by in vivo RT and correlated with poorer RT response and disease-free survival
rate. High expression of Rab25 in the radioresistant cells enhanced the transportation of EGFR to cell sur-
face upon ligand stimulation, and blockage of Rab25 reduced the clonogenicity and aggressive phenotype
of radioresistant cancer cells. These provide the evidence indicating that Rab25 plays a critical role in
radiation-induced aberrant transportation of EGFR, and thus the Rab25-EGFR pathway is a potential ther-
apeutic target to re-sensitize radioresistant cancer cells.
RESULTS
Rab25 Is Correlated with Tumor Response to RT
To identify key factors associatedwithNPC radioresistance, a profile of 84 cell death-related genes (Qiagen)
was analyzed inCNE2R versus its wild-type counterpart CNE2 (Guo et al., 2003; Li et al., 2013; Fu et al., 2019).
This pair of cells showed different morphology, EMT potential, and radiation-induced apoptotic cell death
(Figures S1A–S1C). Among the short list of genes upregulated in radioresistant NPC cell CNE2R, Rab25, the
only protein involved in cargo recycling, showed a 7-fold increase in comparison with CNE2 cells (Fig-
ure S1D). The enhanced Rab25 protein levels were then further identified in CNE2R and in three radioresist-
ant LUAD (A549R, H358R, and H157R) cells You et al., 2014 (Figure 1A) and two chemo-resistant cancer cell
lines, ovarian cancer SKOV3R and NPC CNE1-TR cells Hou et al., 2017; Zhang et al., 2012; Zhou et al., 2015
(Figure S3A). We also observed a significant increased expression of Rab25 in lung xenografts that received
one dose of radiation (Figure 1B), suggesting that radiation might induce Rab25 expression.
To elucidate why expression of Rab25 could be induced by a single dose of radiation, we assume that such
a quick induction of Rab25 expression may well be mediated at a transcriptional level. Thus, we sought
candidate transcriptional factors in the 500-bp promoter region of Rab25 gene by a prediction database
JASPAR (http://jaspar.genereg.net/) and found that there were two binding sites of Stat5 in the promoter
of Rab25 (Figure S1E). As reported by us (Fu et al., 2019) and others (Hasselbach et al., 2005; Maranto et al.,
2018), STAT5 is one of the important transcriptional factors responsive to irradiation. In CNE2R cells,
expression of Stat5a or Stat5b was much higher than in CNE2 cell and could be induced by a single
dose of radiation (Figures S1F and S1G). We also observed an induction for protein levels of both Rab25
and Stat5 in CNE2 cell after a single-dose radiation (Figure S1H). Knockdown of Stat5a and Stat5b by small
interfering RNA (siRNA) in CNE2R cell dramatically decreased the expression of Rab25 (Figure S1I). The
above results suggested that Stat5 might be an important transcriptional factor for Rab25 and might regu-
late the radiation-induced expression of Rab25.
We constructed a radioresistant xenografts model to study whether Rab25 expression is linked to radiore-
sistance in vivo. Briefly, we injected CNE2 cells subcutaneously into the flank of nude mice (P0), and when
xenografts volume reached 200 mm3, we passaged the xenograft into another mice (P1). From P1 passage,
xenografts were irradiated at 5 Gy two times when their volume reached 200mm3. Xenografts had received
a total dose of 110 Gy when we transplanted tumor for 11 passages (Figure 1C). Compared with P1 (only
transplant for one passage), P11 tumor growth became non-responsive to radiotherapy after 5 Gy*2 treat-
ments (Figure S2A). The enhanced Rab25 immunohistochemistry (IHC) staining was observed in three of
four P11 xenografts, whereas no enhanced IHC staining was detected in four P0 xenografts, demonstrating
that Rab25 can be up-regulated in tumors that received radiotherapy in vivo, or in other words, Rab25 was
enhanced in radioresistant tumors (Figures 1D). In addition, the Rab25 IHC staining in sham P4 tumor (just
transplanted for four passages without irradiation) was not increased, suggesting that transplantation
alone might not induce Rab25 expression (Figure S2B).
To further examine Rab25-mediated tumor aggressive phenotype, IHC staining of Rab25 was conducted
on 101 tumor tissues of patients with NPC who received upfront standard radiotherapy in Xiangya Hospital
in recent 5 years. According to the treatment outcomes evaluated usingmagnetic resonance imaging (MRI)
and the Response Evaluation Criteria in Solid Tumors (RECIST) used in the clinic, patients were categorized
into three groups: complete response (CR), partial response (PR), and stable disease (SD). Rab25 expres-
sion was then evaluated in these three groups. All 17 SD samples (100%) and 33 of 47 (70.2%) PR samples
showed strong Rab25 staining, whereas only 8 of 37 (21.6%) of the CR samples were Rab25 positive (score
higher than 2, Figures 2A and S2C). However, Rab25 expression was not significantly correlated with
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histological stage, lymph node metastasis, age, or tumor size (Table S1), further suggesting that Rab25 is a
potential biomarker for predicting the radiotherapy response. An analysis based on the Cancer Genome
Atlas (TCGA) revealed that Rab25 is highly expressed in various tumors (Figure 2B and Table S2), including
LUAD, which exhibits much higher expression of Rab25 than adjacent normal tissues (Figure 2B). The data
from TCGA showed that both overall survival (OS) and disease-free survival (DFS) of the patients with LUAD
with high Rab25 expression had worse outcomes than those with low Rab25 expression (Figures 2C and
2D), which suggested a role of Rab25 in tumor progression and therapeutic response.
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Figure 1. Induction of Rab25 Is Involved in Acquired Tumor Radioresistance
(A) Increased Rab25 expression in radioresistant lung cancer cells (H157R, H358R, and A549R) and NPC cells (CNE2R)
derived from the surviving residues of corresponding wild-type counterparts treated by radiation with fractionated doses.
(B) Schematic (top) and IHC staining of Rab25 in A549 xenografts treated with or without local irradiation, 2 Gy per day for
2 days (bottom). The average Rab25-positive cells in tumors were quantified and are shown in the right bar graph. Scale
bar, 50 mm. n = 3, mean G SD, *p < 0.05.
(C) Schematic diagram for establishment of radioresistant xenograft model. CNE2 cells were injected subcutaneously into
the right flanks of nude mice, and when tumors reached a volume of approximately 200 mm3, radiotherapy was delivered
to the local tumor (5 Gy per day for 2 days; total dose = 10 Gy). On day 5 after last irradiation, the tumors were removed
and one part of tumor tissues was fixed for IHC analysis and another part of tumor tissues was inoculated subcutaneously
into the right flank of another mouse (P1). When the volume of the re-planted tumors in the P1 mice reached
approximately 200 mm3, radiotherapy was delivered again with the same dose, and such treatment was repeated for
11 cycles (P11). The radiosensitivity of tumors from P1 and P11 mice was measured by transplanting the tumors from
P1 and P11 mice and irradiating with 5 Gy 3 2 when tumor reached 200 mm3.
(D) Representative IHC staining of Rab25 in P1 and P11tumors (left). The average Rab25-positive cells in tumors
were quantified (six fields were randomly selected for each xenograft) and shown in the right. Scale bar, 50 mm. n = 18,
mean G SD, **p < 0.01.
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Down-Expression of Rab25 Suppresses RTKs-Mediated Signaling Pathways
RTK-mediated signaling is among themost frequently activated pathways that regulate cancer progression
and therapeutic response. We observed that the content of EGFR was increased in radio- or chemo-resis-
tant cells, whereas the downstream pathways, including Akt and Erk signaling, were hyperactive (Figures
3A and S3A). In NPC clinical samples, the EGFR expression level and the treatment response were closely
correlated in CR and SD groups (Figures 3B and S3B), whereas the levels of EGFR and Rab25 expression
A
B
C D
Figure 2. Rab25 Is Linked with Poor Prognosis and Less Responsiveness of Patients with NPC to Radiotherapy
(A) RT responsiveness of 101 patients with NPC was correlated with Rab25 expression levels; clinic response of all patients
was scored as complete response (CR), partial response (PR), and stable disease (SD), and expression levels of Rab25 were
scored with four levels (0–4) illustrated in left. Scale bar, 50 mm. (B) Elevated Rab25 expression in a large scale of human
cancers (red) compared with normal tissues (gray). The graph was generated from the GEPIA website (http://gepia.
cancer-pku.cn/) and was based on the transcriptional level of Rab25 in an array of human cancer from multiple cohorts of
TCGA study. The median expression of Rab 25 presented as transcripts per million (TPM) was chosen in each cancer type,
and the case number of each cancer type was illustrated in Table S2. Right, Rab25 expression summarized from 483
patients with LUAD and 347 normal lung tissues (meanG SD, *p < 0.05). (C) Overall survival or (D) disease-free survival of
patients with LUAD generated using the log rank test based on Rab25 expression in LUAD tissues from the TCGA cohort.
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Figure 3. Rab25 Is Involved in the Activation of EGFR Pathway
(A) Immunoblotting of EGFR and phosphorylation status of Akt at Ser473 and Erk at Thr202 and Tyr204 in three pairs of lung
radioresistant cells.
(B) Scores of EGFR IHC staining were shown as percentage for EGFR IHC analysis with 4 as the highest and 0 the lowest
expression. Representative IHC imaging were shown in Figure S3B.
(C) Co-expression of Rab25 and EGFR in 101 NPC tissues corresponding to the patients grouped as CR, PR, and SD. The
intensity of IHC staining is scored from 0 to 1 (for ‘‘no signal’’) to 4 (for ‘‘strongest signal’’). Rab25 and EGFR staining
intensity from each patient was compared as two datasets in a column table. R value was calculated using GraphPad Prism
software and the p value was calculated by two-tailed analysis and confidence interval is 95%.
(D) The relative phosphorylation of RTKs in H358R cells and H358R transfected with siRab25. Total proteins were extracted
and screened simultaneously using R&D Systems Human Phospho-Receptor Tyrosine Kinase (RTK) Array Kit. The spot
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was positively associated, indicating these two molecules contributed to NPC radioresponse (Pearson
r = 0.4, p = 0.00005; Figure 3C).
Previous studies (Caswell et al., 2007) and our current data demonstrated that Rab25 could regulate the
cellular anti-anoikis ability controlled by RTK-mediated signaling. Thus, we suspected that Rab25 might
regulate activities of RTKs and their downstream signaling pathways. In radioresistant cells with silenced
Rab25, protein array analyses showed that the levels of some RTK molecules, including RYK, EphB6,
EphB2, andMet, had significantly decreased (Figures 3D, 3E, S3C) and the downstream signaling activation
was inhibited after Rab25 suppression in CNE2R cells (Figure 3E). Furthermore, a decrease in not only EGFR
content but also components of the downstream signaling pathways was verified in NPC CNE2R cell and
LUAD A549R cell (Figure 3F).
Rab25 Is Involved in Endosomes Transport of EGFR
We wondered that Rab25 may play a key role in signaling radioresistance via EGFR transportation. Using
structured illumination microscopy (SIM) super resolution technology, we observed several red circles (rep-
resents Rab25 positive endosome) contained green dots (represents EGFR molecule) and red dots were
co-localized with green dots (Figure 4A). We then carried out an immunoprecipitation assay using anti-
Rab25 antibody in CNE2R cells and observed the association between Rab25 and EGFR (Figure 4B). To
further validate their association, we performed Duolink in situ proximity ligation assay (PLA) and detected
numerous EGFR/Rab25 interaction signals representing Rab25 in close proximity to EGFR. The signals for
co-localization (red dots) were enhanced at 1 h post irradiation, suggesting radiation promoted the inter-
actions between Rab25 and EGFR (Figure 4C).
To characterize the effect of Rab25-positive endosomes on EGFR intracellular endosome distribution, we
analyzed the co-localization rate of EGFR with early endosome marker EEA1 in radioresistant cells after
downregulating Rab25. Rab25 knockdown led to a significant reduction of EGFR in EEA1-positive early en-
dosomes (Figures 4D and 4E), implying that Rab25 might prevent EGFR degradation by routing EGFR to
EEA1-positive early endosomes. Consistently, when treating cells with cycloheximide (CHX) to inhibit
EGFR synthesis, we observed that the half-life of EGFR was shortened in Rab25-depleted cells (Figure 4F).
These results suggest that Rab25-positive endosomes transport EGFR away from late endosomes to pre-
vent its degradation and to maintain active signaling.
Rab25 Transports EGFR onto the Cell Surface upon EGF Stimulation
Next, we examined whether high expression of Rab25 could enhance the membrane content of EGFR. The
radioresistant cancer cells exhibited higher level of EGFR on cell surface than that on parental cells (Fig-
ure 5A), and EGFR immunostaining of Rab25-knockdown CNE2R cells showed that Rab25 knockdown
caused significant reduction of membrane distribution of EGFR (Figure S4A). Then we tracked the mem-
brane content of EGFR at different times after stimulating cell with EGF. The membrane content of
EGFR in CNE2R or A549R cells was consistently much higher than that in parental cells after EGF stimulation
(Figure 5B). In addition, overexpression or knockdown of Rab25 markedly impacted the tyrosine phosphor-
ylation of EGFR (Figures 5C and 5D), further indicating that Rab25 influenced EGFR activity.
To clarify whether membrane content alteration of EGFR mediated by Rab25 was on account of
the variation in ligand-induced endocytosis, we stimulated cells with two doses of Alexa Fluor 488-EGF
(1 or 100 ng/mL) to monitor EGF uptake in CNE2R cells with or without Rab25 knockdown. Flow cytometry
analysis showed that, regardless of the EGF concentration, no difference of the rate of EGF uptake was
observed between the two types of cells, indicating that Rab25-mediated regulation of the membrane
EGFR content was not due to a variation in the coated vesicle formation rate (Figure 5E). The membrane
Figure 3. Continued
intensities were quantified using ImageJ software. The values for control cells (blue box) were set as 1, and the values
of siRab25 (red box) were shown relative to the control, n = 3, mean G SD, **p < 0.01.
(E) Expression of phosphorylated EGFR, HER2, c-Met, and the associated downstream signal molecules was analyzed by
PathScan RTK signaling antibody array kit in CNE2R cell (control) and CNE2R transfected with Rab25 siRNA. The spot
intensities were quantified using ImageJ software. The values for control cells (blue) were set as 1, and the values of siRNA
(red) were shown relative to the control. Results represent mean G SD for three analysis. *p < 0.05, **p < 0.01.
(F) Down-expression of Rab25 reduced the expression of EGFR and the activation of associated signaling pathways in
radioresistant cells.
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content of EGFR was decreased when we knockdown Rab25 in CNE2R or A549R cell (Figure 5F), which was
supported in other therapeutic-resistant cell lines, including radioresistant H358R and H157R LUAD cells
and Taxol-resistant ovarian carcinoma SKOV3R cells (Figures S4B–S4E).
We then examined whether the transportation route of internalized EGFR was influenced by Rab25. A
‘‘pulse-chase’’ experiment Kondapalli et al., 2015 was performed to determine the rate of recycling of inter-
nalized EGFR. Cells were incubated with a fixed concentration of EGF (1 ng/mL) for 10 or 30 min (stimula-
tion), washed with acid to remove surface EGF, and subsequently transferred the cells back to 37C for 10–
40 min (rest). At the end of the chase, the amount of cell surface EGFR was quantified by FACS analysis. The
results showed that during the ‘‘chasing phase’’ the surface content of EGFR in radioresistant H358R cells
was quickly recovered to the original level after 10 min, whereas the content of EGFR in parental cells was
only less than 60% of the original level (Figure 5G). In Rab25-overexpressing and control NPC cells, both
A
B C D
F
E
Figure 4. Rab25 Binds and Prevents EGFR Degradation
(A) Images of confocal microscopy of A549R cells stained with antibodies of Rab25 and EGFR and DAPI. White arrows
indicate the merged signals. Scale bar of right picture is 2.5 mm.
(B) Rab25 was immunoprecipitated from CNE2R cells, followed by immunoblotting of EGFR and Rab25.
(C) CNE2R cells treated with sham or 5 Gy radiation for 24 h were stained with EGFR and Rab25 antibodies and subjected
to Duolink in situ PLA. Scale bar, 25 mm. Bar diagrams, the number of interactions per cell. Mean G SD, **p < 0.01.
(D) Images of confocal microscopy of cells stained with antibodies of EEA1 and EGFR.
(E) Co-localization of EGFR and early endosome marker EEA1. Mean G SD, **p<0.01.
(F) Immunoblotting of EGFR in CNE2R cells transfected with control or shRab25 and treated with either vehicle (0.01%
dimethyl sulfoxide) or 10uM cycloheximide (Chx) for the indicated time.
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Figure 5. Rab25 Enhances EGFR Recycle and Increases Cell Surface Content of EGFR
(A) Immunoblotting of EGFR on cell surface in A549 and A549R cells. PMCA1 was used as plasma membrane loading
control, and Hsp90 was used as cytosol protein control.
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cells had decreased by 25% of the initial value after EGF stimulation for 30 min. During the chasing phase, a
small fraction of EGFR molecules was recycled to the cell surface in control cells, and the EGFR membrane
content remained at a low level. In contrast, after 40 min of chasing, the membrane content of EGFR nearly
reverted to the initial level in Rab25-overexpressing cells (Figure 5H). In addition, suppression of Rab25 in
SKOV3R cells severely impaired the trafficking of EGFR onto the cell surface (Figure 5I). We next examined
whether hyperactive EGFR signaling in radioresistant cells was dependent on Rab25 expression. After
knockdown Rab25 by lenti-viral transduction of Rab25-specific shRNA in radioresistant cells, we found
that the phosphorylation of EGFR and activation of Akt and Erk declined when the cells were treated
with ligand or radiation (Figures 5J, 5K, and S4F–S4H) and re-expression of Rab25 in Rab25 knockdown cells
compensated the declination, suggesting that Rab25 actively participates in regulating RTK protein levels
and activity in response to irradiation or ligands. Taken together, these results indicate that Rab25-endo-
somes are responsible for the enhanced level and activity of EGFR in therapeutic-resistant cancer cells.
Blocking Rab25 Sensitizes Radioresistant Cells with Reversed EMT
The high expression of Rab25 in radioresistant cells indicated its close association with radioresistance. FACS
analysis showed an increase in the extent of apoptosis in Rab25-knockdown cells at 24 and 36 h (Figure 6A) after
cells received a 4-Gy dose radiation. Colony formation assay further demonstrated that Rab25 depletion mark-
edly suppressed the clonogenicity of CNE2R cells andA549R cells after radiation treatment, especially when the
cells receiveda6-or 8-Gydose (Figures 6BandS5A).Wealsoexamined theeffect of Rab25 knockdownon radio-
sensitivity of radioresistantH358R cells and chemo-sensitivity of taxol-resistantCNE1-TR cells and observed that
both cells becamesensitive to therapeutic treatmentuponRab25 knockdown (Figures S5BandS5C). Thus, these
results revealed that Rab25 expression contributed to therapeutic resistance of cancer cells. In addition, we also
employed a TKI erlotinib to treat PC9 cell to study whether EGFR inhibition could sensitize cancer cells to irra-
diation. After erlotinib treatment, FACS analysis showed that cells became sensitive to radiation, suggesting
that TKIs treatment might increase cell radiosensitivity (Figure S5D).
Most cancer cells exhibit an EMT-like transition when they acquire resistance to therapies. The loss of
epithelial features and acquisition of mesenchymal characteristics enable resistant cells to spread more
quickly and be more invasive. We observed that, after knocking down of Rab25, the expression of EMT
markers in radioresistant CNE2R cells could be reversed (Figure S5E) and cells were sensitive to induction
of apoptosis and anoikis (Figures 6C, S5F, and S5G) with inhibited invasiveness (Figure 6D). These obser-
vations were further confirmed in taxol-resistant CNE1-TR cells and radioresistant H358R cells transfected
with Rab25-specific siRNAs, which showed increased cell apoptosis rates induced by ultra-low attachment
treatment. In addition, the sphere formation ability of CNE2R cells was dramatically decreased after Rab25
knockdown (Figure 6E).
Blocking Rab25 Resensitizes Radioresistant Tumors
We wonder whether Rab25 is a therapeutic target to breakdown tumor radioresistance. Using in vivo xeno-
graft tumors of CNE2R-shcontrol or CNE2R-shRab25 cells, we found that silencing of Rab25 gene
Figure 5. Continued
(B–D) (B) The kinetics of ligand-induced internalization of EGFR in radioresistant CNE2R cell or A549R cell.
Phosphorylated tyrosine (p-Tyr) was immunoprecipitated from CNE2R cells with knockdown (C) or overexpression (D) of
Rab25, followed with immunoblotting of EGFR.
(E) Endocytotic rate of EGF in CNE2R cell or CNE2R cells with down-expression of Rab25. The amount of alex-488
conjugated EGF was quantified by flow cytometry.
(F) Quantification of the cell surface content of EGFR in cells or in cells with down-expression of Rab25. EGFR cell surface
content was performed every 5 min after stimulation with 1 ng/mL EGF. Right, flow cytometry analysis at each time point
was plotted as histogram.
(G) Left, cell surface EGFR recycling rate in H358 or H358R cells pretreated with 1 ng/mL EGF for 10 min before which cells
had been starved for 6 h. Right: flow cytometry analysis at each time point was plotted as histogram.
(H and I) (H) Cell surface EGFR recycling rate in CNE2 and CNE2 cells stably transfected with Rab25 or in ovarian
carcinoma taxol-resistant SKOV3R cells with knockdown of Rab25 (I). Mean G SD, **p < 0.01.
(J) EGF-induced activation of RTK-mediated signaling pathways in A549R cells and A549R with siRNA-mediated
knockdown of Rab25. Cells were first incubated for 6 h in serum-free medium and then treated with 1 ng/mL EGF for
indicated time.
(K) Immunoblotting of radiation-induced activation of RTK pathways in A549R cells or in A549R with siRNA-mediated
knockdown of Rab25. Cells were irradiated at 4 Gy.
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expression significantly suppress tumor growth (Figure 6F, blue line versus green line). From day 16, the
radiation-treated group of shRab25 xenografts showed an obvious reduction in tumor growth rate
compared with other three groups (Figure 6F). The knockdown efficiency of Rab25 in these xenografts
was confirmed using IHC staining (Figure 6G), and down-expression of EGFR (Figure 6H) was observed
A
B
C D
E
F G H
Figure 6. Blocking Rab25 Enhances Cell Death and Radio-Sensitization In Vitro and In Vivo
(A) Apoptosis rate in CNE2R or CNE2R cells transfected with shRab25 24 or 36 h after 4 Gy radiation.
(B) Clonogenic survival of radiation in radioresistant cells with shRab25-mediated knockdown. The clonogenicity was
calculated by normalizing to the control cells that received 0 Gy IR, and the normalized clonogenic survival rates are
shown on the bottom (n = 3, mean G SD, *p < 0. 05, **p < 0. 01).
(C) Apoptosis rate after cells cultured in ultra-low attached wells for indicated time.
(D) Images and capacity of trans-well invasion (au, arbitrary units; n = 3; mean G SD, **p < 0.01).
(E) Mammosphere formation assay (n = 3 in each group, mean G SD, **p < 0.01), scale bar, 50 mm.
(F) Radiosensitivity of xenograft tumors generated with control and CNE2R-shRab25 cells and treated with 2 Gy at day 12
and day 13 (n = 5; mean G SD, **p < 0.01).
(G) Representative images of IHC staining for Rab25 in NPC xenografts with or without irradiation. The average
Rab25-positive cells in tumors were quantified and shown in the right bar graph. Scale bar, 50 mm. MeanG SD, *p < 0.05,
**p < 0.01.
(H) Representative images of IHC staining for EGFR in NPC xenografts with or without irradiation. The average EGFR-
positive cells in tumors were quantified and shown in the right bar graph. Scale bar, 50 mm. mean G SD, **p < 0.01.
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in xenografts knockdown Rab25. These results demonstrate that Rab25-mediated EGFR enhancement is
critically required for tumor cells to survive radiation.
DISCUSSION
This study reveals a potential therapeutic target of Rab25-mediated EGFR enhancement in radioresistant
LUAD and NPC cells. Rad25 has been linked with a poor prognosis in several cancer types (Cheng et al.,
2004; Zhang et al., 2013a), and our current results further demonstrate a function of Rab25 in recycling
EGFR, which is responsible for the acquired radioresistance in LUAD and NPC cells. Rab25 interacts with
EGFR to reduce the degradation of EGFR leading to the enhancement of EGFR richness on cell surface
causing an increased RTK-mediated signaling and aggressive phenotype of the radioresistant cancer cells.
These findings suggest a model of Rab25-mediated EGFR recycling in acquired radioresistance, in which
the formation of Rab25-EGFR conjugates in the cytoplasm is able to reduce the degradation of eternized
EGFR and to recycle them to the cell surface required for the surviving tumor cells to keep the essential
proliferation capacity and regrow under genotoxic stress conditions such as radiotherapy.
Although long being discovered, few studies has revealed the exact function of Rab25. The association be-
tween Rab25 and wild-type EGFR was first observed in lung cancer, where Rab25 inhibition promoted the
endocytosis of EGFR and thus contributed to gefitinib sensitization (Jo et al., 2014). Jeong et al. recently re-
ported that Rab25-induced tumor EMT was regulated by integrin/EGFR/VEGF-A/Snail axis, suggesting
Rab25-EGFR interaction plays an important role in tumor migration (Jeong et al., 2018). In this paper, we first
and directly proved that Rab25 regulated EGFR content and activation by fast recycling EGFR to cell surface
upon ligand or stress stimulation, adding a significant information on tumor adaptive response to therapeutic
radiation. Not only EGFR content but also phosphorylation status of EGFR was influenced by Rab25 expres-
sion. EGFR recruitment into endosomes was dependent onGrb2 (Johannessen et al., 2006; Jiang et al., 2003),
which in this study was observed to co-localize with Rab25. In addition, GAB1, a scaffold protein in amplifi-
cation of EGFR-mediated PI3K activation (Mattoon et al., 2004), was found in Rab25-EGFR co-localized com-
plex, suggesting that EGFR located in Rab25-endosome was active in signaling transduction.
Rab25-mediated EGFR recycling will also provide mechanistic insights in revealing tumor acquired resis-
tance to TKIs. EGFR TKIs alone or in combination with other treatment strategies are now the recommen-
ded treatment for patients with lung cancer harboring mutant EGFR. However, patients with mutant EGFR
eventually develop acquired TKI resistance and patients harboring wild-type EGFR show poor response to
first-generation TKIs and serious side effect for second- or third-generation TKIs (Liao et al., 2015).
Moreover, EGFR mutation in non-small-cell lung cancer of adenocarcinoma histology ranges from roughly
12%–47% (Midha et al., 2015), implying that there are a lot of patients with lung cancer with wild-type EGFR
who cannot benefit from TKIs treatment. Our finding that wild-type EGFR was tightly controlled by Rab25
provided a possibility to develop generation of TKIs, especially after identification of Rab25-EGFR interac-
tion motif. In addition, we observed that other RTK-like receptors including Met, RYK, EphB2, and EphB6
were also regulated by Rab25, suggesting that Rab25-endosome might be one of the main RTK trafficking
route in radioresistant cells. Considering the cross talk between different RTKmembers, we believed Rab25
might be a promising target for inhibiting RTK-mediated signaling pathway.
In this study, we illustrated that Rab25 was acquired for radioresistance in twomajor solid tumors treated by
radiotherapy, which was linked with EMT enhancement and survival advantage under anchorage-indepen-
dent environment. The EMT plasticity of a cancer cell is a major feature of therapy-resistant tumors. The
adaptive tumor resistance and increased metastasis constitute the major failure of anti-cancer therapy
causing 90% of cancer mortalities (Ahmed et al., 2018) in which acquired EMT-like phenotype and
enhanced survival ability are linked with RTK-mediated pathway (Buchheit et al., 2014). RTK-mediated
signaling pathways are often hyperactive in EMT program, which were activated by growth factors and
then rendered the tight junction of cells (Forster, 2008; Ray and Jablons, 2009). The EGFR content on
the cell surface is functionally important for activating EGFR downstream signaling. Here, we observed a
rapid recovery of the EGFR surface level in Rab25 over-expressing cells. High expression of Rab25 greatly
promotes its binding to EGFR and accelerated the recovery of EGFR content on cell membrane. Downre-
gulation of Rab25 led to a reversal of EMT-like markers and reduced anti-anoikis ability, indicating that EMT
occurrence in therapeutic-resistant cells is partially Rab25 dependent. Our current results provide new in-
sights into themechanisms of how therapeutic-resistant cells acquire EMT plasticity, suggesting that Rab25
is a potential effective target to block EGFR signaling and tumor proliferation.
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By analyzing samples from 101 patients with NPC, we demonstrate that the expression of Rab25 in NPC
was highly related to the radiotherapy response. However, the level of Rab25 expression did not seem to
be associated with the histological grade, tumor size, or regional nodal metastasis. In patients with lung
cancer, the same is true that high expression of Rab25 renders a poorer survival rate. The majority of pa-
tients with lung cancer are clinically diagnosed at advanced stages with a poor survival rate (Zappa and
MOUSA, 2016). Particularly, these patients who lack surgical indications are recommended to receive
radiotherapy (Postmus et al., 2017). For NPC, owing to its anatomical features and relative sensitivity
to radiation, radiotherapy has been a first-line treatment (Zhang et al., 2013b). Although radiotherapy
can control local tumor, radioresistance always occurs and becomes a challenging obstacle for curative
lung cancer and NPC treatment. This highlights the Rab25-dependent effect on radiotherapy efficacy
in patients with cancer.
Given the importance of Rab25 and the EGFR signaling pathway in human cancers in general, Rab25 may
also represent a predictive marker for the cancer radiotherapy response and a potential candidate target
for enhancing therapeutic efficacy. Further elucidating the molecular mechanisms underlying Rab25
controlled activation and duration of EGFR signaling may invent additional targets for desensitization of
resistant tumor cells.
Limitation of the Study
In this study, we found that hyperactivation of RTK-mediated signaling pathways in therapeutic-resistant
cells was due to rapid recycling of EGFR mediated by Rab25. Although a positive correlation between
Rab25 expression and other RTKs such as MET and IGF1R was also observed, the detailed clarification
was not performed, which warrants further investigation.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100997.
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Figure S1 High expression of Rab25 in radioresistant cells was regulated by Stat5, 
Related to Figure 1. 
a Morphological characterization of CNE2 and CNE2R cells (magnification: ×100). b 
Western blotting assay of EMT markers in CNE2 or CNE2R cells. α-Tubulin was used 
as a loading control. c Apoptosis rate of CNE2 or CNE2R cells after culturing in ultra-
low attachment wells for indicated time. d Volcano plot of differentially genes between 
CNE2 and CNE2R cells. The total RNAs extracted from CNE2R or CNE2 cells were 
reverse-transcribed into single-stranded cDNA. Quantitative RT-PCR for cell death-
related genes was performed using the RT² Profiler™ PCR Array Human Cell Death 
Pathway Finder, and data analysis was performed using a website-based analysis tool 
from the Qiagene GeneGlobe Data Analysis Center. e Diagram to show the predicted 
binding sites of Stat5 in -500bp region of Rab25. f Transcriptional level of Stat5a and 
Stat5b in CNE2 and CNE2R cells, n=3, mean ± SD, **p < 0.01. g Transcriptional level 
of Stat5a and Stat5b in CNE2 cells irradiated at 8Gy with indicated time. n=3, mean ± 
SD, **p < 0.01. h Protein level of Rab25 or Stat5 in CNE2 cells irradiated at 8Gy with 
indicated time. i Transcriptional level of Rab25, Stat5a, and Stat5b in CNE2R cells or 
in CNE2R cells with Stat5 knockdown. n=3, mean ± SD, **p < 0.01. 
 
  
Figure S2 Rab25 was enhanced in radioresistant P4 xenografts, Related to Figure 
2. 
a Growth curve of tumors from transplanted P1 and P11 mice following radiation. 
Tumors were irradiated with 5 Gy x 2 when tumor reached 200 mm3. Four mice were 
used in each group and data are represented as mean ± SD. The statistical significance 
between groups was determined with the two-tailed unpaired Student’s t test. P values 
are presented as star marks in figures: *p < 0.05. b Representative IHC staining of 
Rab25 in sham P4 (passage alone without radiation) and P4 xenografts. scale bar, 50 
μm. c Scores of negative, low, medium or high levels of Rab25 were shown as 
percentage for Rab25 IHC analysis.  
 
  
Figure S3 EGFR was hyperactive in therapeutic cells and patients samples, 
Related to Figure 3. 
a Western blot analysis of EGFR and its downstream Erk and Akt signaling pathways 
in two taxol-resistant cell lines (NPC cell CNE1-TR and ovarian carcinoma cell 
SKOV3R). b Representative IHC staining of EGFR in tissues of NPC patients with 
different radiotherapy responses. The ASCO-CAP guideline 201336 was used for 
interpretation of EGFR IHC data. Expression levels of EGFR were classified into five 
grades (score 0-1: 0-25% , score 2: 25%-50%, score 3: 50%-75%, score 4: >75%). scale 
bar 50μm. c Protein array analysis with different exposure time.   
 
  
Figure S4 Surface content of EGFR was regulated by Rab25, Related to Figure 5.  
a Immonoflourence of EGFR in CNE2R cell or in CNE2R cells with Rab25 knockdown. 
b Quantification of cell surface EGFR content in H358R cells transfected with 
siControl or siRab25 mix over time following stimulation with 1 ng/ml EGF. c EGFR 
cell surface content by flow cytometry. Each time point for each cell line contained 
three replicates. Mean ± SD, *p < 0.05. d,e Taxol-resistant SKOVR3 or radioresistant 
157R cells were firstly transfected with control or siRab25 mixture for 24h. Then, the 
transfected cells were stimulated with 1 ng/ml EGF for 30 mins. Cells were collected 
and analyzed for surface EGFR content with Alexa647-conjugated EGFR antibody by 
FACS. f Activity of EGFR downstream signaling Akt and Erk in H358 or H358R cells 
after short-time EGF stimulation. n=3, mean ± SD, *p < 0.05. g Rab25 expression in 
three CNE2R-shRab25 cells and in CNE2R-shRab25 cell transfected with Rab25. h 
Down-expression of Rab25 reduced the expression of EGFR and the activation of 
associated signaling pathways in radioresistant cells. 
 
  
Figure S5 Rab25 knockdown by reverted cell EMT-like phenotype and sensitized 
cell to radiation, Related to Figure 6. 
a Gating strategies for apoptosis induced by radiation in CNE2R cells with or without 
transfection of shRab25. b Rab25 expression in therapeutic-resistant cells was 
transfected with Rab25 siRNA mixture. c Rab25 knockdown increased the apoptosis 
rate of therapeutic-resistant cells treated with taxol or radiation. The ratio of apoptotic 
cells was measured by FACS using Annexin V and PI double staining method. d 
Erlotinib increased the radiation-induced apoptosis of EGFR mutant PC9 cells. Cellls 
were treated with 5uM Erlotinib alone or combined with 4Gy irradiation. The ratio of 
apoptotic cells was measured by FACS using Annexin V and PI double staining method. 
n=3, mean ± SD, **p < 0.01. e Decreased expression of EMT-markers in CNE2R cells 
knockdown with Rab25. f Gating strategies for apoptosis induced by detachment in 
CNE2R cells with or without transfection of shRab25. g Rab25 knockdown increased 
the apoptosis rate of therapeutic-resistant cells cultured in low-attachment culture 
dishes for the indicated time. n=3, mean ± SD, **p < 0.01. 
 
Table S1. Transcription of Rab25 in different cancers, Related to Figure 2 
Variables       n 
Rab25 expression 
p-value* 
negative/low moderate high 
Age 
>50 years 33 6 22 5 
0.214 
<=50 years 68 15 46 7 
Tumor size 
T1 1     0  1 0 
0.0812 
T2 28     6 19 3 
T3 30 8 18 4 
T4 42 8 29 5 
Stage 
II 5 0  5 0 
0.073 
III 30 8 20 2 
IVa 60     12 40 8 
IVb 6 1  3 2 
Lymph node metastasis 
N0 8      0  7 1 
0.5116 N1/2 64     13 44 7 
N3 29      8 17 4 
*Statistical significance was determined by the 2 test.  
 
  
Table S2. Patient samples for Rab25 transcript analysis*, Related to Figure 2. 
Tumor 
abbreviation 
Tumor name 
Normal 
(number) 
Tumor 
(number) 
BLCA Bladder urothelial carcinoma 28 404 
BRCA Breast invasive carcinoma 291 1085 
CESC 
Cervical squamous cell carcinoma and 
endocervical adenocarcinoma 
13 306 
CHOL Cholangio carcinoma 9 36 
COAD Colon adenocarcinoma 349 275 
LUAD Lung adenocarcinoma 347 483 
LUSC Lung squamous cell carcinoma 338 486 
OV Ovarian serous cystadenocarcinoma 88 426 
PAAD Pancreatic adenocarcinoma 171 179 
PRAD Prostate adenocarcinoma 152 492 
READ Rectum adenocarcinoma 318 92 
STAD Stomach adenocarcinoma 211 408 
TGCT Testicular germ cell tumors 165 137 
THCA Thyroid carcinoma 337 512 
THYM Thymoma 339 118 
UCEC Uterine corpus endometrial carcinoma 91 174 
UCS Uterline carcinosarcoma 78 57 
* Information was from TCGA. 
 
Transparent Methods  
Cell lines 
All of the radioresistant cancer cells were generated by saving the surviving residues 
of cells following the regimen of clinically mimic fractionated ionizing radiation 
(from Monday to Friday, 2Gy/day, total dose is 60 Gy) (Guo et al., 2003).Lung cancer 
cell lines A549, A549R, H157, H157R, H358, and H358R, were gifted from 
Xingming Deng (You et al., 2014). STR test was run for CNE2 and CNE2R cells. 
PC9 cell were bought from the cell bank of type culture collection of Chinese 
academy of sciences with STR authentication. Radioresistant nasopharyngeal 
carcinoma cell line CNE2R (Li et al., 2013), the paclitaxel-resistant cell lines CNE1-
TR and SKOV3R (Zhang et al., 2012, Hou et al., 2017, Zhou et al., 2015) were 
cultured following the published work. All of the cells except A549 and A549R were 
cultured in RPMI-1640 medium (Hyclone) with 10% FBS and 1% 
penicillin/streptomycin (Invitrogen, Thermo Fisher Scientific). A549 and A549R cells 
were cultured in DMEM/F12 medium (Hyclone) supplemented with 10% FBS and 
1% penicillin/streptomycin (Invitrogen, Thermo Fisher Scientific). All cell lines were 
cultured at 37 °C in a 5% CO2 incubator.  
Reagents and antibodies 
Reagents include EGF (RD, catalog # 236-EG, 10 ng/ml) and EGF-AlexaFluor 488 
(Thermofisher, catalog # E13345, 10 ng/ml, Thermofisher). The R&D Systems™ 
Human Phospho-Receptor Tyrosine Kinase (RTK) Array Kit (catalog # ARY001B) 
was purchased from R&D Company. 
The following antibodies were used for western blot: anti-Rab25 from Sigma 
(catalog # R8532, 1:500 dilution); anti- PMCA1 (catalog # ab76020, 1: 5000 
dilution), from abcam, anti-Akt, (catalog #9272, 1:1000 dilution),  anti-phospho-Akt 
S473 (catalog#4060, 1:1000 dilution), anti-ERK1/2 (catalog#4695, 1:1000 dilution), 
anti-E-cadherin (catlog#14472, 1:1000 dilution), anti-N-cadherin (catlog#13116, 
1:1000 dilution), anti-Vimentin (catlog#5741, 1:1000 dilution), anti-p-Tyr 
(catalog#8954, 1:2000 dilution), anti-phospho-EGFR (Y1068) (catalog#2234, 1:1000 
dilution) and anti-phospho-ERK1/2 (catalog#4370, 1:1000 dilution), HSP90 
(catalog#4877, 1:1000) from Cell Signaling; and anti-EGFR (catalog#sc-03, 1:1000 
dilution), anti-GAPDH (catalog#sc-47724, 1:1000 dilution), anti-actin (catalog#sc-
58673, 1:1000 dilution), and anti-Tubulin (catalog#sc-166729, 1:1000 dilution) from 
Santa Cruz.  
The following antibodies were used for immunofluorescence and Duolink assays: 
anti-EGFR (catalog#ab-30, Abcam, 1:200 dilution); anti-Rab25 
(catalog#HPA010872, Sigma, 1:100 dilution); and anti-EEA1 (catalog#3288, Cell 
Signaling, 1:100 dilution). The following antibody was used for flow cytometry: 
Alexa Fluor® 647 mouse anti-human EGFR (catalog#563577, BD Pharmingen, 
5ul/test). The following antibody was used for IHC: anti-Rab25 from Sigma 
(catalog#R8532, sigma,1:100 dilution), anti-EGFR (catalog#ab-30, Abcam,1:200 
dilution). 
Rab25 transfection 
Cells were transfected with DharmaFECT1 siRNA transfection reagent (Dharmacon) 
as described by the manufacturer’s guidelines for 48 h. The siRNAs were generated 
on the basis of the following sequences: Rab25: 1# 5’-
GGAAGACCAATCTACTCTC-3’, and 2# 5’-TTGAGCTAGCCTTTGAGAC-3’, 
and 3# 5’-GAACTCATTGCGCGTGAATC-3’, Stat5a: 1# 5’- : 
GCGCTTTAGTGACTCAGAA-3’, 2# 5’- ACAGAACCCTGACCATGTA-3’, 
Stat5b: 1# 5’-ATGGGACTCAGTAGATCTT-3’, 5’- 
GCATCACCATTGCTTGGAA-3’ (Fu et al., 2019),  and the control siRNA 
sequence was 5’-TTCTCCGAACGTGTCACGT-3’.  
Construction of lentiviruses and cell transduction 
Full-length Rab25 was cloned into the pLV-EF1α-MCS-IRES-Bsd lentiviral vector 
with a blasticidin-selectable marker (cDNA-pLV03, Biosettia). The Rab25 short 
hairpin RNA (shRNA) sequence (sh1# 
GATCCGGGAAGACCAATCTACTCTCTCAAGAGAGAGAGTAGATTGGTCTT
CC TTTTTTACGCGTG, sh2#GATCCG 
TTGAGCTAGCCTTTGAGACTCAAGAGAGTCTCAAAGGCTAGCTCAA 
TTTTTTACGCGTG, sh3#GATCCGGAACTCATTGCGCGTGAATCTCAAGAGA 
GATTCACGCGCAATGAGTTC TTTTTTACGCGTG) and the control shRNA 
sequence (GATCCG 
TTCTCCGAACGTGTCACGTTCAAGAGAACGTGACACGTTCGGAGAA 
TTTTTTACGCGTG) were cloned into Lenti-X™ shRNA Expression Systems 
(Clontech) with a puromycin-selectable marker. The Gag-Pol + Rev expression vector 
and VSV-G expression vector packaging plasmids were co-transfected with the pLV-
EF1α-MCS-IRES-Bsd-Rab25 construct or the shRab25 construct in HEK293T cells 
for 48 h according to the manufacturer’s instructions. The virus was collected 48 h 
after transfection, and cells were selected with blasticidin (8 μg/ml) or puromycin (1 
μg/ml), respectively.  
Immunoblotting 
Cells were harvested and lysed in RIPA buffer plus protease inhibitor cocktail and 
phosphatase inhibitor cocktail (Selleck). The protein samples were separated by SDS-
PAGE under reducing conditions and transferred onto polyvinylidene difluoride 
(PVDF) membranes (0.22 and 0.45 μm, Millipore, Bedford, MA, USA). 
Subsequently, the membrane was blocked with 5% skim milk in TBST buffer (TBS 
containing 0.1% Tween-20) for 1 h at room temperature and then hybridized with 
primary antibody with gentle agitation overnight at 4°C. After being washed with 
TBST three times, the membrane was incubated with HRP-conjugated secondary 
antibody (Santa Cruz) for 1 h at room temperature. Bands were detected with a Pierce 
ECL Western Blotting Substrate detection system (Thermo Scientific) and visualized 
using a Gel Doc™ XR+ System (Bio-Rad). Three independent experiments were 
performed. 
RNA extraction and real-time quantitative PCR 
Total RNA was extracted from cells according to the manufacturer’s protocol using 
TRIzol reagent (Invitrogen). The dissolved RNA sample was measured on a 
spectrophotometer to determine the concentration and quality before being converted 
to complementary DNA (cDNA). RNA samples were reverse transcribed using a 
SuperScript III First-Strand Synthesis SuperMix for qPCR Kit (Life Technologies, 
California, USA), and quantitative real-time PCR (qRT-PCR) analysis was performed 
using a CFX-96 Real-time PCR System (Bio-Rad, Hercules, CA, USA). The values 
were expressed as fold changes compared with the corresponding values for the 
control using the 2–ΔΔCt method. 
PCR array analysis 
Quantitative RT-PCR for cell death-associated genes was performed using a Cell 
Death Pathway Finder PCR Array (PAHS-212Z, QIAGEN, MD, USA) according to 
the manufacturer’s protocol. For data analysis, a web-based software from data 
analysis center of QIAGEN was used. The fold-changes were then calculated and 
expressed as log-normalized ratios of the values from the CNE2R cells to those of the 
CNE2 cells. 
Tumor xenografts and radiotherapy 
All of the animal experiments were approved by the Animal Ethics Committee of 
Xiangya Hospital Central South University and followed the Guidelines of Animal 
Handling and Care of Central South University. The BALB/c nude mice used in our 
animal model were 4- to 6-week-old female mice. Cells (5x105 cells/mouse) stably 
transduced with or without the Rab25 shRNA lentivirus were suspended in 100 μl of 
RPMI-1640 medium mixed with Matrigel (1:1) and injected subcutaneously into the 
left flank of the mice for NPC or lung cancer tumor formation. Tumor growth was 
recorded every other day with a caliper according to the following formula: tumor 
volume = the shortest diameter2 × the largest diameter × 0.5. After the tumors reached 
a volume of approximately 200 mm3, the irradiation treatment groups were irradiated 
with 2 Gy locally at the tumor every two days, for a total dose of 4 Gy.  
For establishment of radio-insensitive NPC xenografts, CNE2 cells (5x105 
cells/mouse) were injected subcutaneously into the left flank of the mice for NPC 
tumor formation (named P0 mice). When the tumors reached a volume of 
approximately 200 mm3, tumor tissues were harvested and divided into equally sized 
pieces (volume of 1-2 mm3) immediately after removal from the mouse. 
Approximately 5-6 tumor pieces were then inoculated subcutaneously into the left 
flank of recipient mice for tumor formation (named P1 mice); the remaining tissue 
was fixed in 10% formalin for IHC analysis. An X-ray treatment of 5 Gy was 
administered locally to the tumor for two days when the tumor volume of the P1 mice 
reached 200 mm3. After 5 days of treatment, the mice were sacrificed, and the tumors 
were immediately cut into small pieces for inoculation into the left subcutaneous flank 
of recipient mice for tumor formation (named P2 mice). When the tumor pieces had 
been transferred to the P11 mice, we compared the growth rate of tumors between P2 
and P11 mice. Data are presented as the tumor volume (n=4, Mean ± SD, *p<0.05). 
Statistical analysis was performed using the Student’s t test and the software 
Graphpad Prism.  
Immunohistochemistry  
Paraffin-embedded slides were incubated at 70°C for 90 min and then deparaffinized 
with xylene and rehydrated. Endogenous peroxidase activity was quenched with 3% 
H2O2 solution for 15 min at 37°C, and antigen retrieval was performed in a pressure 
cooker using sodium citrate buffer (10 mM, pH 6.0). Sections were immuno-stained 
with antibodies against Rab25 and EGFR. All immunostainings were performed with 
the avidin-biotin-peroxidase complex technique in combination with 
diaminobenzidine (DAB), and the slides were counterstained with hematoxylin and 
eosin (H&E) for surgical pathology specimens. The use of NPC patient tumor 
samples in this study was approved by the Human Ethical Committee of Xiangya 
Hospital of Central South University.  
The immunoreactive proteins in the tissue were evaluated with scores based on 
the proportion of positive tumor cells. Random 3-5 sections of each sample and 5-6 
high-power fields (HPF) of each section were used for analysis and quantification. 
Fields with different staining intensity were counted separately when the staining was 
not homogeneous. According to the IHC staining intensity, the following criteria were 
used for interpretation of IHC data. High expression was defined as strong staining 
intensity in more than 75% of tumor cells (score=4); medium expression was 
moderate staining intensity in more than 50% of tumor cells (score=3); low 
expression was weak staining intensity in more than 25% of tumor cells (score=2); 
negative expression was weak staining in less than 25% of tumor cells (score=0-1). 
Immunofluorescence 
Cells were quickly rinsed with pre-warmed PBS and fixed with 4% paraformaldehyde 
(PFA) in PBS for 20 min at 37°C, permeabilized in 0.5% Triton X-100 for 20 min and 
blocked with BlockAidTM blocking solution (Thermo Fisher) for 1 h. After labeling 
with primary antibodies overnight at 4°C, cells were washed in PBS and incubated 
with Alexa Fluor-conjugated secondary antibodies for 45 min at room temperature. 
All antibody incubations were performed in BlockAidTM blocking solution. The 
coverslips were mounted with DABCO anti-fade agent on glass slides and imaged 
using DeltaVision OMX SR (GE) equipped with a 63x/1.4 numerical aperture oil-
immersion objective. For quantification of the EGFR internalization in early and late 
endosomes or to evaluate the co-localization of EGFR and Rab25, the software 
MetaMorph was used to analyze the co-localization of signals from the Rab25 and 
EEA1 channels. 
Immunoprecipitation 
Cells were fixed with 4% PFA for 15 min and lysed in RIPA buffer. Protein A/G 
magnetic beads were first suspended in binding buffer (50 mM Tris, 150 mM NaCl, 
0.1%-0.5% Triton 100 or Tween 20, pH 7.5) and then incubated with 5 μg Rab25 
antibody or normal rabbit IgG antibody for 1 h at room temperature with end-over-
end rotation. After the supernatant was removed, 200 mg of cell lysate was added to 
each tube, which was incubated with rotation for 10 min at room temperature. The 
immunoprecipitated proteins were released by boiling for 5 min at 95°C in SDS–
PAGE sample buffer. The magnetic beads were removed with a magnetic separator 
before the samples were loaded onto a 12% SDS–PAGE gel.  
Duolink proximity ligation assay 
The in situ proximity ligation assay was performed using a Duolink® In Situ Red 
Starter Kit for Mouse/Rabbit (DUO92101, Sigma) according to the manufacturer’s 
instructions. Briefly, cells were seeded onto coverslips and circled with a hydrophobic 
pen the day before the experiment. After treatment, the cells were fixed, 
permeabilized, blocked, and then incubated with primary antibodies at 4°C overnight. 
After washing, the oligonucleotide (Minus and Plus)-conjugated secondary antibodies 
were added and incubated for another hour at 37°C. Subsequently, cells were washed 
and incubated with ligation solution for 30 min at 37°C. The ligated nucleotide circles 
were amplified using polymerase via the addition of amplification solution and 
incubation for 100 min at 37°C. The slides were washed briefly, and Duolink® In Situ 
Mounting Medium with DAPI (DUO82040, Sigma) was added to each sample to 
stain cell nuclei for fluorescence microscopy. The visualized fluorescence spots 
represented the clusters of protein-protein interactions. 
EGF uptake and EGFR internalization assay  
Cells were serum-starved for 6 hours and used for either EGF uptake or EGFR 
internalization assays. For the quantitative EGF uptake assay, cells were treated with 
1 ng/ml or 100 ng/ml EGF-Alexa488 (Invitrogen) for the indicated time at 37°C. For 
the EGFR internalization assay, cells were treated with 1 ng/ml EGF (RD) for the 
indicated time at 37°C. A plate incubated in RPMI-1640 medium without ligand for 
30 min or 180 min was used as a control. EGF uptake was halted by placing the cells 
on ice followed by two washes in ice-cold phosphate-buffered saline (PBS). To 
remove surface-bound EGF, cells were washed three times for 5 min each with cold 
acid buffer (RPMI-1640/0.2% BSA, pH 3.5 adjusted with HCl). The ‘pulse-chase’ 
assay was conducted as previously described (Kondapalli et al., 2015). Cells were 
treated 1 ng/ml EGF for 30 min and then transferred to ice to halt EGFR 
internalization. After three washes with cold acid buffer, the plates used for observing 
the EGFR recycling process were cultured in RPMI 1640 with glutamine (Hyclone) in 
an incubator at 37°C and 5% CO2 for the indicated time. The EGFR recycling process 
was halted by transferred the plates to ice. For the quantitative EGF uptake assay, 
cells were detached from the culture dishes, centrifuged at 300 ×g for 5 min at 4°C 
and suspended in 0.2% BSA in PBS. For the EGFR internalization assay, cells were 
detached and incubated with Alexa 647-EGFR antibody in PBS for 20 min. After 
washing once with 0.2% BSA in PBS, cells were fixed in 4% PFA in PBS. Flow 
cytometry was performed using a Millipore Guava® easyCyte HT Sampling Flow 
Cytometer.  
Flow cytometry analysis of anoikis and apoptosis 
An anoikis resistance assay was performed by seeding cells in a 6-well ultra-low 
attachment surface polystyrene culture dish (Corning 3473) using regular culture 
medium. For cell apoptosis analysis, the cells were collected at different time points 
and resuspended in Annexin V binding buffer supplemented with Annexin V and 
propidium iodide (Roche). Anoikis was quantitated by flow cytometry, and the degree 
of apoptotic cell death (%) was determined by flow cytometry (Millipore) using 
Annexin V-FITC/PI staining.   
Colony-forming assay 
Cells were seeded at a density of approximately 200 cells per well in six-well plates 
and irradiated with various doses 24 h after plating. The cells were then cultured for 
12 days to allow colony formation. Only the single clones that contained more than 50 
cells were counted. During colony growth, the culture medium was replaced every 3 
days. Each treatment was performed in triplicate. 
Tumor sphere formation assay 
Single-cell suspensions were seeded into 6-well ultra-low attachment surface 
polystyrene culture dish (Corning 3473) at a density of 500 cells/ml. Cells were 
grown in serum-free medium, supplemented with B27 (Life Technology), 20 ng/ml 
EGF (Biovision), 20 ng/ml basic-FGF, and 4 µg/ml heparin (VWR). Cells were 
cultured for 10 days and tumor spheres were counted, sphere size were measured and 
calculated under light microscopy and collected for further experiments. Three 
independent experiments were done in triplicate. 
Kaplan-Meier survival analyses 
TCGA RNA-seq data for LUAD samples were obtained from UCSC Xena browser 
(http://xena.ucsc.edu/). The overall survival or disease-free survival of LUAD patients 
were evaluated using the Kaplan–Meier method, and statistical differences in survival 
times were determined using the log-rank test as described elsewhere. The cohort 
include 720 lung adenocarcinoma samples obtained from Kaplan-Meier Plotter 
(http://kmplot.com/analysis/index.php?p=service&cancer=lung) were used to 
generate the overall survival analyses of LUAD patient based on Rab25 (Affy ID, 
218186_at) status. Patients were split by median expression of Rab25. The cohort 
include 478 LUAD samples were obtained and analysis by GEPIA website for disease 
free survival analysis. A log rank test was used to test for differences of more than 
one survival curve. 
Quantification and statistical analysis 
Data was presents as mean ± standard deviation (SD). GraphPad Prism was used for 
statistical analysis. ANOVA analysis was used for comparison study of more than two 
data groups and student’s t-test was used to compare two groups of independent 
samples. Pearson correlation test was utilized to evaluate the association of staining 
intensities of EGFR and Rab25 in NPC patients who received radiotherapy. Image J 
was used to quantified and normalized data.  Significance was indicated as follow: 
NS, not significant; * p<0.05; ** p<0.01.  
